3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma, T-Cell, Peripheral
3
Myelodysplastic Syndromes
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Uveal Melanoma
1
Neuroendocrine Tumors
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Eye Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Neuroendocrine
1
Blast Crisis
1
Interventions
pembrolizumab
44
Gemcitabine
23
enfortumab vedotin
21
Nivolumab
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
belinostat
×
1 year
×
Clear all
NCT05154994
2026-05-07
RESOLVE
University of Utah
Phase 1
Active not recruiting
9 enrolled